DK1572230T3 - Placenta alkalisk phosphatase til at kontrollere diabetes - Google Patents

Placenta alkalisk phosphatase til at kontrollere diabetes

Info

Publication number
DK1572230T3
DK1572230T3 DK03796758.5T DK03796758T DK1572230T3 DK 1572230 T3 DK1572230 T3 DK 1572230T3 DK 03796758 T DK03796758 T DK 03796758T DK 1572230 T3 DK1572230 T3 DK 1572230T3
Authority
DK
Denmark
Prior art keywords
alkaline phosphatase
treatment regimens
human
methods
diabetes
Prior art date
Application number
DK03796758.5T
Other languages
English (en)
Inventor
Zoltan Kiss
Original Assignee
Zoltan Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoltan Lab filed Critical Zoltan Lab
Priority claimed from PCT/US2003/038838 external-priority patent/WO2004054609A1/en
Application granted granted Critical
Publication of DK1572230T3 publication Critical patent/DK1572230T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03796758.5T 2002-12-12 2003-12-05 Placenta alkalisk phosphatase til at kontrollere diabetes DK1572230T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/317,916 US7048914B2 (en) 2002-12-12 2002-12-12 Placental alkaline phosphatase to control diabetes
US10/441,992 US7014852B2 (en) 2002-12-12 2003-05-20 Alkaline phosphatase to induce weight loss or to reduce weight gain
PCT/US2003/038838 WO2004054609A1 (en) 2002-12-12 2003-12-05 Placental alkaline phosphatase to control diabetes

Publications (1)

Publication Number Publication Date
DK1572230T3 true DK1572230T3 (da) 2011-01-03

Family

ID=32506246

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03796758.5T DK1572230T3 (da) 2002-12-12 2003-12-05 Placenta alkalisk phosphatase til at kontrollere diabetes

Country Status (6)

Country Link
US (4) US7048914B2 (da)
EP (1) EP1733734B1 (da)
AT (1) ATE480256T1 (da)
DE (1) DE60334147D1 (da)
DK (1) DK1572230T3 (da)
ES (1) ES2354976T3 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054609A1 (en) * 2002-12-12 2004-07-01 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7048914B2 (en) * 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US20080279843A1 (en) * 2003-12-09 2008-11-13 Essential Skincare, Llc Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
AU2005210581B2 (en) 2004-02-04 2010-06-24 Am-Pharma B.V. Use of alkaline phosphatase for the detoxification of LPS present at mucosal barriers
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
US7557081B2 (en) * 2004-05-27 2009-07-07 Essential Skincare, Llc Alpha-1-acid glycoprotein for the treatment of diabetes
US20070149440A1 (en) * 2005-12-28 2007-06-28 Essential Skincare, Llc Transferrin and transferrin-based compositions for diabetes treatment
US20070148140A1 (en) * 2005-12-28 2007-06-28 Zoltan Laboratories Llc Compositions and methods to enhance viability and function of islet cells
WO2007075199A1 (en) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
US20090317372A1 (en) * 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
US20130251701A1 (en) * 2010-10-22 2013-09-26 Zoltan Kiss Consulting Alkaline phosphatase to correct insulin resistance, hyperinsulinemia, and dyslipidemia
US8679480B2 (en) * 2011-06-20 2014-03-25 Wisconsin Alumni Research Foundation Method to inhibit neuropathic pain by intrathecal injection of protein phosphatases
KR102166110B1 (ko) 2014-01-24 2020-10-16 에이엠-파마 비.브이. 키메라 알칼리성 포스파타제-유사 단백질
CN106459143A (zh) 2014-01-24 2017-02-22 安-法玛公司 碱性磷酸酶的下游处理
AU2016229976B2 (en) 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
EP3600257B8 (en) 2017-03-21 2023-06-21 Theriva Biologics, Inc. Alkaline phosphatase formulations
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
EP3768302A4 (en) 2018-03-20 2021-12-15 Synthetic Biologics, Inc. INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
CA3146738A1 (en) 2019-07-18 2021-01-21 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
WO2022150034A1 (en) * 2021-01-06 2022-07-14 Zoltan Laboratories, Llc Placental alkaline phosphatase for starting early treatment of cancer patients exhibiting no detectable loss of body and muscle weight as yet to prevent or reduce the loss of muscle proteins
US20240165209A1 (en) * 2021-02-16 2024-05-23 Zoltan Laboratories, Llc Placental alkaline phosphatase for reducing the loss of red blood cells, white blood cells, and platelets in chemotherapy treated cancer patients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4030995A (en) 1976-07-13 1977-06-21 Sigma Chemical Company Alkaline phosphatase isoenzyme determination
GB1594389A (en) * 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
IT1108964B (it) 1978-01-20 1985-12-16 Sclavo Inst Sieroterapeut Composizione adatta all'analisi della fosfatasi alcalina e metodo utilizzante la stessa
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
DE3007226A1 (de) 1980-02-27 1981-09-10 Erich 2400 Lübeck Hofacker Arzneikapsel
SU1138410A1 (ru) 1982-09-10 1985-02-07 Астраханский государственный медицинский институт им.А.В.Луначарского Способ выделени термостабильной плацентарной щелочной фосфатазы
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
JPS61277626A (ja) 1985-05-31 1986-12-08 Sugiura Shinyaku Kaihatsu Kenkyusho:Kk ス−パ−オキシドジスムタ−ゼを高濃度に含有する胎盤エキスおよびその製法
DE3836971C1 (da) * 1988-10-31 1990-05-17 Weck, Wolfgang, Dr.Med., 6990 Bad Mergentheim, De
SU1814764A3 (ru) 1990-04-20 1995-03-20 Тихоокеанский институт биоорганической химии Дальневосточного отделения АН СССР Способ получения средства для лечения гнойно-некротических ран
EP0526630A4 (en) 1991-02-22 1993-08-11 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
CA2137275A1 (en) * 1992-06-03 1993-12-09 Richard L. Eckert Bandage for continuous application of biologicals
WO1995005455A1 (en) * 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5932779A (en) 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
US6627425B1 (en) 2000-06-02 2003-09-30 Millennium Pharmaceuticals, Inc. Human glucose-6-phosphatase molecules and uses thereof
US7011965B2 (en) 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US7048914B2 (en) * 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
WO2004054609A1 (en) * 2002-12-12 2004-07-01 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
WO2007075199A1 (en) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals

Also Published As

Publication number Publication date
ES2354976T3 (es) 2011-03-21
US20040115185A1 (en) 2004-06-17
DE60334147D1 (de) 2010-10-21
US7858085B2 (en) 2010-12-28
EP1733734B1 (en) 2020-01-22
US7048914B2 (en) 2006-05-23
ATE480256T1 (de) 2010-09-15
US7014852B2 (en) 2006-03-21
EP1733734A3 (en) 2011-09-28
US20090130080A1 (en) 2009-05-21
US8603464B2 (en) 2013-12-10
EP1733734A2 (en) 2006-12-20
US20040120940A1 (en) 2004-06-24
US20110123513A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
DK1572230T3 (da) Placenta alkalisk phosphatase til at kontrollere diabetes
LU91544I2 (fr) Alpha alglucosidase
NO20020211L (no) Anvendelse av deskarboksyloratadin for fremstilling av et farmasöytisk preparat for behandling av medisinske tilstander
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
WO1991004058A3 (en) Treatment of conditions and disease
PL362687A1 (en) Spaced drug delivery system
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
IT1305306B1 (it) Uso della pirenoxina per la protezione dei tessuti corneali ininterventi di fotocheratectomia.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
DE69127459D1 (de) Zellprofilerationsmatritze und ihre verwendung
WO1998030223B1 (en) Cytokine related treatments of disease
AU3401093A (en) Therapeutic agent for threatened abortion
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
BR0312463A (pt) Prática terapêutica ou profilática contra o diabetes mellitus e a obesidade; métodos de redução do nìvel de glicose no sangue; supressor de apetite; método de prevenção ou tratamento contra o diabete mellitus e a obesidade; e método de supressão de apetite
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
DE602004025040D1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
WO2002043566A3 (en) Devices and methods for treating low blood sugar levels
KR890001555A (ko) 요산 배설용 조성물
EP1051973A4 (en) OPTICAL PAPILLAR CIRCULATION IMPROVING AGENTS
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
Westendorp et al. RIGHT ATRIUM ANP
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят